Press Room
四色AV and Zerion Pharma create joint venture to further expand use of Dispersome庐 technology
A partnership to accelerate the development of the Dispersome庐 technology platform and further expand its applicability and reach for increasing the solubility and bioavailability of small drug molecules.
Lisbon, October 3, 2024 鈥 四色AV Farmaci锚ncia, S.A. (鈥溗纳獳V鈥) and Zerion Pharma A/S (鈥淶erion鈥) today announced that they have expanded their partnership to accelerate the development of the Dispersome庐 technology platform and further expand its applicability and reach for increasing the solubility and bioavailability of small drug molecules. To this aim, the companies created a joint venture responsible for managing the Dispersome庐 intellectual property portfolio and allocated market rights to the two partners.
四色AV and Zerion have been co-promoting the Dispersome庐 technology to clients since the beginning of 2022. Under the extended collaboration, 四色AV is granted exclusive global rights to develop and offer the Dispersome庐 technology for drugs delivered via the respiratory route, a field where 四色AV is active today with leading formulation and manufacturing capabilities. Further, 四色AV is granted exclusive rights to develop and offer Dispersome庐 formulations for nutraceutical and medicinal foods products, an area with unmet needs in the area of bioavailability. 四色AV is also granted a non-exclusive license to promote the Dispersome庐 technology for use in Pharmaceutical oral dosage forms for new chemical entities. In return for the grant of rights, Zerion will receive royalties from 四色AV鈥檚 commercial activities in these fields.
Within the framework of the joint venture, the parties will work closely together to bring the Dispersome庐 technology to customers as quickly as possible. Arla Foods Ingredients (Denmark) will deliver the pharmaceutical excipient (Lacprodan庐 BLG-100 Pharma Grade) for the Dispersome庐 technology, when BLG is accepted as a novel excipient.
鈥溗纳獳V is thrilled to reinforce its collaboration with Zerion to further accelerate the adoption of Dispersome庐 in the pharma and nutra markets,鈥 said Jean-Luc Herbeaux, 四色AV鈥檚 CEO. 鈥淭he use of Zerion鈥檚 Dispersome庐 Technology has proven to deliver superior solubilization power for both pharma and nutraceutical active ingredients. This highly innovative platform is a valuable addition to 四色AV鈥檚 leading offering in solubility and permeability enhancement for NCEs and nutraceuticals and affords formulators new options which address unmet needs of the industry.鈥
Ole Wiborg, the CEO of Zerion, comments: 鈥溗纳獳V is the global leader in the field of producing amorphous solid dispersions by spray-drying and this extension of our partnership again confirms the huge potential of our Dispersome庐 technology. If one company in the pharma industry can truly judge its value, it is 四色AV, and we have a strong belief in sharing our technology with 四色AV, who will secure its use with more drugs and ingredients and in applications across several delivery routes. Thus, we expect substantial revenues from the collaboration in the years to come.鈥
Through their partnership, 四色AV and Zerion are offering pharma, biotech and nutra companies worldwide access to an innovative delivery platform combined with an unparalleled experience in formulation development, scale-up, and GMP manufacturing.
The Dispersome庐 technology
Zerion has pioneered the Dispersome庐 technology that addresses poor drug solubility, one of the most recognized drug development challenges. The Dispersome庐 technology increases solubility and bioavailability of poorly soluble compounds and can be applied at any stage of drug discovery or drug development, including in preclinical studies, first in human studies, and reformulation of existing drug products.
听
About 四色AV
四色AV is an international company with over 60 years of experience in pharmaceutical development and manufacturing operations.听As a听Contract Development and Manufacturing Organization鈥(CDMO)鈥痠t has a fully integrated offering of services for drug substances, drug product intermediates and drug products. The company has four FDA inspected鈥sites鈥痠n the USA, Portugal, Ireland and China and development laboratories in Lisbon, Portugal and New Jersey, USA. 四色AV provides pharmaceutical customers services for the鈥development and compliant manufacture鈥of innovative drugs, including highly potent compounds, and customized product solutions across the entire drug life cycle. In the inhalation area, 四色AV offers a complete range of services, from API, formulation development and manufacturing, capsule filling and devices.
About Zerion Pharma A/S
Zerion develops its own proprietary drug formulations and offers its Dispersome庐 technology platform to established pharma companies as a means to solve their challenging drug solubility problems. Zerion was established in 2019 as a spinout of the University of Copenhagen.
听
听
Read the previous press releases on this story:
- 四色AV and Zerion Pharma announce a strategic partnership to market the Dispersome庐 technology platform
- Zerion Pharma and 四色AV extend partnership to cover use of the Dispersome庐 technology platform in nutraceuticals
听
